Zhang_2022_ChemMedChem_17_e202100653

Reference

Title : Synthesis and Evaluation of a Class of Compounds Inhibiting the Growth of Stromal Antigen 2 (STAG2)-Mutant Ewing Sarcoma Cells - Zhang_2022_ChemMedChem_17_e202100653
Author(s) : Zhang N , Lin KF , Yang C , Peruski S , Pati D , Gilbertson SR
Ref : ChemMedChem , 17 :e202100653 , 2022
Abstract :

STAG2 (SA2) is a critical component of the cohesin complex that regulates gene expression and the separation of sister chromatids in cells. Mutations in STAG2 have been identified in over thirty different types of cancers including myeloid leukaemia, non-small cell lung, bladder and Ewing sarcoma. Selectively inhibiting cancer cells lacking of STAG2 is an attractive approach for the cancer therapy. Here we report that a small molecule, StagX1, identified through a high-throughput screening, inhibits the growth of Ewing sarcoma cells possessing mutant STAG2. A new synthetic route to the StagX1 scaffold and new versions of the molecule along with their activity in a cell viability assay are reported.

PubMedSearch : Zhang_2022_ChemMedChem_17_e202100653
PubMedID: 35018729

Related information

Substrate StagX1

Citations formats

Zhang N, Lin KF, Yang C, Peruski S, Pati D, Gilbertson SR (2022)
Synthesis and Evaluation of a Class of Compounds Inhibiting the Growth of Stromal Antigen 2 (STAG2)-Mutant Ewing Sarcoma Cells
ChemMedChem 17 :e202100653

Zhang N, Lin KF, Yang C, Peruski S, Pati D, Gilbertson SR (2022)
ChemMedChem 17 :e202100653